FOXC1 Activators
FOXC1 activators constitute a diverse and influential group of chemicals that intricately modulate the transcription factor FOXC1 through various signaling pathways. This category encompasses a range of compounds, including Niclosamide, Verteporfin, Resveratrol, Heparin, FH535, GW9662, IWP-2, SB431542, DAPT, XAV-939, LY294002, and Nicotinamide, each playing a pivotal role in the regulation of FOXC1 expression and activity. Niclosamide, a noteworthy FOXC1 activator, exerts its effects indirectly by disrupting the Wnt/β-catenin signaling pathway. Its inhibition of canonical Wnt signaling influences TCF/LEF transcriptional activity, leading to altered expression of downstream targets, including FOXC1. Similarly, Verteporfin indirectly activates FOXC1 by disrupting the YAP-TEAD complex, thereby influencing genes associated with FOXC1-mediated cellular processes. Resveratrol takes a different approach, indirectly activating FOXC1 through modulation of the Notch signaling pathway. Its enhancement of Notch signaling, achieved through increased γ-secretase activity, results in the activation of Notch target genes, including FOXC1. Heparin, another FOXC1 activator, operates through the TGF-β signaling pathway. By binding to TGF-β ligands, Heparin impedes their interaction with cell surface receptors, subsequently modulating FOXC1-related cellular processes.
The intricate interplay between FOXC1 and these diverse signaling pathways sheds light on interventions for conditions associated with dysregulated FOXC1 activity. Understanding the specific biochemical mechanisms of these FOXC1 activators provides valuable insights into the complexity of FOXC1 regulation and its pivotal role in cellular processes. In summary, the multifaceted nature of FOXC1 activation by these chemicals, whether through Wnt/β-catenin, YAP-TEAD, Notch, or TGF-β signaling pathways, underscores the versatility of approaches in modulating FOXC1 expression and function. This diversity in activation mechanisms opens avenues for targeted interventions and further emphasizes the importance of comprehensively exploring the intricate regulatory networks involving FOXC1 in various physiological and pathological contexts.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Niclosamide | 50-65-7 | sc-250564 sc-250564A sc-250564B sc-250564C sc-250564D sc-250564E | 100 mg 1 g 10 g 100 g 1 kg 5 kg | $38.00 $79.00 $188.00 $520.00 $1248.00 $5930.00 | 8 | |
Niclosamide is a FOXC1 activator that acts indirectly by inhibiting the Wnt/β-catenin signaling pathway. It disrupts the canonical Wnt signaling by inhibiting TCF/LEF transcriptional activity, leading to altered expression of downstream targets, including FOXC1, and subsequent activation of FOXC1-related cellular processes. | ||||||
Verteporfin | 129497-78-5 | sc-475698 sc-475698A | 10 mg 100 mg | $354.00 $2764.00 | 5 | |
Verteporfin is a FOXC1 activator that indirectly modulates the protein by inhibiting the YAP-TEAD complex. By disrupting YAP-TEAD interaction, Verteporfin influences the expression of genes involved in cellular proliferation and survival, including FOXC1. This indirect activation of FOXC1 contributes to the regulation of cellular processes associated with YAP-TEAD signaling. | ||||||
Resveratrol | 501-36-0 | sc-200808 sc-200808A sc-200808B | 100 mg 500 mg 5 g | $80.00 $220.00 $460.00 | 64 | |
Resveratrol is a FOXC1 activator that acts indirectly by modulating the Notch signaling pathway. It enhances Notch signaling by promoting γ-secretase activity, leading to the activation of Notch target genes, including FOXC1. This indirect activation of FOXC1 through Notch signaling contributes to the modulation of cellular processes associated with FOXC1-mediated pathways. | ||||||
Heparin | 9005-49-6 | sc-507344 | 25 mg | $119.00 | 1 | |
Heparin is a FOXC1 activator that acts indirectly by influencing the TGF-β signaling pathway. It binds to TGF-β ligands, preventing their interaction with cell surface receptors and subsequently modulating downstream signaling events, including the regulation of FOXC1 expression. This indirect activation of FOXC1 through TGF-β signaling contributes to the modulation of cellular processes associated with FOXC1. | ||||||
β-Catenin/Tcf Inhibitor, FH535 | 108409-83-2 | sc-221398 sc-221398A | 10 mg 50 mg | $182.00 $374.00 | 7 | |
FH535 is a FOXC1 activator that acts indirectly by inhibiting the Wnt/β-catenin signaling pathway. It disrupts the interaction between β-catenin and TCF transcription factors, leading to altered expression of downstream targets, including FOXC1, and subsequent activation of FOXC1-related cellular processes. | ||||||
GW 9662 | 22978-25-2 | sc-202641 | 5 mg | $70.00 | 30 | |
GW9662 is a FOXC1 activator that acts indirectly by modulating the PPARγ signaling pathway. It is a selective PPARγ antagonist, and its inhibition of PPARγ results in the upregulation of FOXC1 expression, contributing to the modulation of cellular processes associated with FOXC1-mediated pathways. | ||||||
IWP-2 | 686770-61-6 | sc-252928 sc-252928A | 5 mg 25 mg | $96.00 $292.00 | 27 | |
IWP-2 is a FOXC1 activator that acts indirectly by inhibiting the Wnt/β-catenin signaling pathway. It promotes the degradation of Wnt proteins, preventing their interaction with cell surface receptors and subsequently modulating downstream signaling events, including the regulation of FOXC1 expression. This indirect activation of FOXC1 through Wnt signaling contributes to the modulation of cellular processes associated with FOXC1. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
SB431542 is a FOXC1 activator that acts indirectly by modulating the TGF-β signaling pathway. It is a selective inhibitor of TGF-β type I receptors, leading to altered downstream signaling events, including the regulation of FOXC1 expression. This indirect activation of FOXC1 through TGF-β signaling contributes to the modulation of cellular processes associated with FOXC1-mediated pathways. | ||||||
DAPT | 208255-80-5 | sc-201315 sc-201315A sc-201315B sc-201315C | 5 mg 25 mg 100 mg 1 g | $40.00 $120.00 $480.00 $2141.00 | 47 | |
DAPT is a FOXC1 activator that acts indirectly by modulating the Notch signaling pathway. It inhibits γ-secretase activity, preventing the cleavage of Notch receptors and subsequent activation of Notch target genes, including FOXC1. This indirect activation of FOXC1 through Notch signaling contributes to the modulation of cellular processes associated with FOXC1-mediated pathways. | ||||||
XAV939 | 284028-89-3 | sc-296704 sc-296704A sc-296704B | 1 mg 5 mg 50 mg | $36.00 $117.00 $525.00 | 26 | |
XAV-939 is a FOXC1 activator that acts indirectly by inhibiting the Wnt/β-catenin signaling pathway. It promotes the degradation of β-catenin, preventing its translocation to the nucleus and subsequent regulation of downstream targets, including FOXC1. This indirect activation of FOXC1 through Wnt signaling contributes to the modulation of cellular processes associated with FOXC1-related pathways. | ||||||